Viking Therapeutics Rises on Obesity Drug Data, Eli Lilly and Novo Fall
📊 LLY — Piyasa Yorumu
▼ down · 60%Viking Therapeutics' positive obesity drug data indicates that Eli Lilly may face competitive pressure. This news could be a negative catalyst for LLY stock in the short term. Technical indicators are currently strong: RSI at 62 and above the MACD signal line, but a correction could come due to the news impact. The price is trading above the SMA20 and SMA50, indicating the trend is still upward. However, competitive concerns may create selling pressure in the short term, so I expect a downward movement.
📊 NVO — Piyasa Yorumu
▼ down · 70%Viking Therapeutics' positive obesity drug data could heighten competition concerns in the sector and create selling pressure on NVO. The stock is already in a strong downtrend: a 5.1% drop in 24 hours, RSI at 24.8 indicating oversold territory, and a negative MACD. The price is trading below its 20-day and 50-day simple moving averages, confirming short-term weakness. The news could reinforce the existing downtrend and increase the likelihood of further downside movement within 1-3 days. However, due to oversold conditions, a rebound buying may occur, so it is prudent to be cautious rather than definitively bearish.